Cabaletta Bio Inc (CABA) Stock Price, Quote & News

Company Profile

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company's lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, systemic lupus erythe...

Industry: Biotechnology

Sector: Healthcare

Phone: 267 759 3100

Website: www.cabalettabio.com

Address:

2929 Arch Street, Suite 600, Philadelphia, United States

Achandler787 Jul. 4 at 2:28 PM

$CABA $LLY

0 · Reply

Achandler787 Jul. 4 at 2:25 PM

$CABA $LILY.X moves evident in the narrowing of focus by eliminating MS trial before it starts in my opinion. PC free Data, manufacturing data and Eli Lily moves coming up. Eli Lily is one of only 16 Trillion dollar companies in the world and they have invested snd are advising this little penny stock $CABA …thats huge in any world.

0 · Reply

Rolo2024 Jul. 4 at 2:14 AM

$CABA I only have 360 shares practically just broke even. I noticed in March 2024 we were at a high of $26 so why is our PT around $13.50 now? Anyone know?

2 · Reply

deweyeggbert Jul. 3 at 11:29 PM

$CABA both eyes on it.

0 · Reply

topstockalerts Jul. 3 at 10:57 AM

$CABA keep an eye on it

0 · Reply

raj4cena Jul. 3 at 3:39 AM

$CABA Any chance of this reaching 5?

2 · Reply

ABDULMOHSEN08 Jul. 3 at 12:50 AM

$CABA What is the price now?😅🤫

1 · Reply

Bronco6970 Jul. 2 at 10:17 PM

$CABA Abdul, where are you? Get ready to feel more pain.

1 · Reply

Achandler787 Jul. 2 at 8:22 PM

$CABA most shorts lose a lot of money. Maybe a couple a pros with real research are successful with mega trends —-not penny stock bio tech flippers. That’s Russian Roulette.

1 · Reply

pleasemoney Jul. 2 at 8:17 PM

$CABA how is your 2.50 eow prediction going @ABDULMOHSEN08? Any more insight to share with us?

0 · Reply

Cabaletta Bio Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

2026-06-03T14:54:15.000Z - 4 weeks ago

Cabaletta Bio presents new data for rese-cel in autoimmune diseases

Jun 3, 2026, 7:35 AM EDT - 4 weeks ago

Cabaletta Bio Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 7:00 AM EDT - 4 weeks ago

Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress

Jun 3, 2026, 7:00 AM EDT - 4 weeks ago

Cabaletta Bio Slides: Corporate presentation

Jun 1, 2026, 8:00 AM EDT - 4 weeks ago

Cabaletta Bio Proxy statement: Proxy filing

May 19, 2026, 4:00 PM EDT - 6 weeks ago

Cabaletta Bio Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference

2026-05-14T14:21:15.000Z - 7 weeks ago

Cabaletta Bio presents new clinical data for rese-cel

2026-05-14T12:08:57.000Z - 7 weeks ago

Cabaletta Bio reports Q1 EPS (39c), consensus (39c)

May 14, 2026, 7:05 AM EDT - 7 weeks ago

Cabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update

May 14, 2026, 7:00 AM EDT - 7 weeks ago

Cabaletta Bio Presents Preconditioning-free Clinical Data and Automated Manufacturing Translational Data for Rese-cel at ASGCT 2026 Annual Meeting

May 14, 2026, 7:00 AM EDT - 7 weeks ago

Cabaletta Bio Quarterly report: Q1 2026

May 14, 2026, 7:00 AM EDT - 7 weeks ago

Cabaletta Bio Earnings release: Q1 2026

May 14, 2026, 7:00 AM EDT - 7 weeks ago

Cabaletta Bio Slides: Corporate presentation

2026-05-04T12:54:08.000Z - 2 months ago

Cabaletta Bio financing overhang concerns should be addressed, says Cantor

May 4, 2026, 6:35 AM EDT - 2 months ago

Cabaletta Bio Announces Pricing of $150 Million Underwritten Offering

2026-04-28T13:02:04.000Z - 2 months ago

Cabaletta Bio, Cellares report 10-year commercial supply agreement for rese-cel

2026-04-28T12:38:26.000Z - 2 months ago

Cabaletta Bio, Cellares enter 10-year commercial agreement

Apr 28, 2026, 8:00 AM EDT - 2 months ago

Cabaletta Bio and Cellares Announce 10-Year Commercial Supply Agreement for Rese-cel

Apr 28, 2026, 8:00 AM EDT - 2 months ago

Cellares and Cabaletta Bio Sign 10-Year Commercial Supply Agreement to Scale Rese-cel

Apr 28, 2026, 8:00 AM EDT - 2 months ago

Cabaletta Bio Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 2 months ago

Cabaletta Bio Proxy statement: Proxy filing

Apr 27, 2026, 5:00 PM EDT - 2 months ago

Cabaletta Bio Announces Multiple Upcoming Presentations, Including Data on Rese-cel without Preconditioning and Rese-cel with Automated Manufacturing, at the ASGCT 2026 Annual Meeting

Apr 20, 2026, 7:00 AM EDT - 2 months ago

Cabaletta Bio Slides: Corporate presentation

Apr 17, 2026, 8:00 AM EDT - 2 months ago

Cabaletta Bio Proxy statement: Proxy filing

2026-04-14T20:36:56.000Z - 2 months ago

Patients dosed with Cabaletta’s rese-cel manufactured on Cellares’ Cell Shuttle

Apr 14, 2026, 4:30 PM EDT - 2 months ago

First Patients Dosed with Cabaletta Bio's Rese-cel Manufactured on Cellares' Automated Cell Shuttle™ Platform

2026-03-24T10:53:15.000Z - 3 months ago

Morgan Stanley and Jefferies Analysts Forecast Over 350% Upside Potential for Cabaletta Bio Stock

JEF MS

2026-03-23T23:20:56.000Z - 3 months ago

Cabaletta Bio price target lowered to $13 from $14 at Morgan Stanley

2026-03-23T18:00:24.000Z - 3 months ago

Cabaletta Bio price target raised to $16 from $15 at Guggenheim

2026-03-23T11:40:46.000Z - 3 months ago

Cabaletta Bio reports Q4 EPS (40c), consensus (47c)

Mar 23, 2026, 7:30 AM EDT - 3 months ago

Cabaletta Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Mar 23, 2026, 7:30 AM EDT - 3 months ago

Cabaletta Bio Annual report: Q4 2025

Mar 23, 2026, 7:30 AM EDT - 3 months ago

Cabaletta Bio Earnings release: Q4 2025

Mar 23, 2026, 7:00 AM EDT - 3 months ago

Cabaletta Bio Slides: Corporate presentation

Mar 3, 2026, 11:10 AM EST - 4 months ago

Cabaletta Bio Transcript: TD Cowen 46th Annual Health Care Conference

Feb 24, 2026, 8:00 AM EST - 4 months ago

Cabaletta Bio to Participate in the TD Cowen 46th Annual Health Care Conference

Feb 12, 2026, 9:30 AM EST - 5 months ago

Cabaletta Bio Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 5, 2026, 8:00 AM EST - 5 months ago

Cabaletta Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

2026-02-04T15:50:25.000Z - 5 months ago

Cabaletta Bio participates in a conference call with William Blair

2026-01-12T13:38:11.000Z - 6 months ago

Cabaletta Bio announces 2026 strategic priorities

Jan 12, 2026, 8:00 AM EST - 6 months ago

Cabaletta Bio Announces 2026 Strategic Priorities

Jan 12, 2026, 7:30 AM EST - 6 months ago

IND Amendment Clearance Obtained for Clinical Manufacturing of Rese-Cel from Cabaletta Bio Using Cellares' Automated Platforms

Jan 11, 2026, 7:00 AM EST - 6 months ago

Cabaletta Bio Slides: Corporate presentation

2026-01-08T12:44:43.000Z - 6 months ago

Cabaletta Bio price target lowered to $14 from $22 at Morgan Stanley

2025-12-10T23:00:19.000Z - 7 months ago

Cabaletta Bio’s treatment of myasthenia gravis granted FDA orphan designation

Dec 5, 2025, 7:00 AM EST - 7 months ago

Cabaletta Bio Slides: Corporate Presentation

Dec 3, 2025, 1:45 PM EST - 7 months ago

Cabaletta Bio Transcript: Citi Annual Global Healthcare Conference 2025

Dec 2, 2025, 8:20 AM EST - 7 months ago

Cabaletta Bio Transcript: Evercore ISI 8th Annual HealthCONx Conference

Nov 17, 2025, 8:30 AM EST - 8 months ago

Cabaletta Bio Transcript: Jefferies London Healthcare Conference 2025

Nov 11, 2025, 10:30 AM EST - 8 months ago

Cabaletta Bio Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

2025-11-10T12:38:12.000Z - 8 months ago

Cabaletta Bio reports Q3 EPS (44c), consensus (46c)

2025-11-10T12:37:22.000Z - 8 months ago

Cabaletta Bio sees cash runway into 2H26

Nov 10, 2025, 7:30 AM EST - 8 months ago

Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 10, 2025, 7:30 AM EST - 8 months ago

Cabaletta Bio Quarterly report: Q3 2025

Nov 10, 2025, 7:30 AM EST - 8 months ago

Cabaletta Bio Earnings release: Q3 2025

Nov 4, 2025, 8:00 AM EST - 8 months ago

Cabaletta Bio to Participate in Upcoming Investor Conferences in November and December

2025-10-31T12:51:01.000Z - 8 months ago

Cabaletta Bio price target raised to $30 from $15 at Cantor Fitzgerald

Oct 27, 2025, 7:00 AM EDT - 8 months ago

Cabaletta Bio Presents Positive Clinical Data and Development Updates for Rese-cel at ACR Convergence 2025

Oct 14, 2025, 8:00 AM EDT - 9 months ago

Cabaletta Bio Announces Appointment of Steve Gavel as Chief Commercial Officer and Award of Inducement Grant

Oct 9, 2025, 12:00 PM EDT - 9 months ago

Cabaletta Bio Presents First Rese-cel Data with No Preconditioning Demonstrating Biologic Activity and Early Clinical Responses at the 2025 ESGCT Annual Congress

Sep 10, 2025, 11:30 AM EDT - 10 months ago

Cabaletta Bio Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Aug 27, 2025, 8:00 AM EDT - 11 months ago

Cabaletta Bio to Participate in Upcoming Investor Conferences in September

Aug 7, 2025, 8:00 AM EDT - 11 months ago

Cabaletta Bio Registration statement: Registration Filing

Aug 7, 2025, 7:30 AM EDT - 11 months ago

Cabaletta Bio Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 7, 2025, 7:30 AM EDT - 11 months ago

Cabaletta Bio Quarterly report: Q2 2025

Aug 7, 2025, 7:30 AM EDT - 11 months ago

Cabaletta Bio Earnings release: Q2 2025

Jun 11, 2025, 9:54 AM EDT - 1 year ago

Cabaletta Bio Announces Pricing of Public Offering of Securities

Jun 11, 2025, 7:00 AM EDT - 1 year ago

Cabaletta Bio Slides: Investor Presentation

Jun 11, 2025, 6:15 AM EDT - 1 year ago

Cabaletta Bio Announces Proposed Public Offering of Securities

Jun 11, 2025, 6:00 AM EDT - 1 year ago

Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress

Jun 4, 2025, 11:05 AM EDT - 1 year ago

Cabaletta Bio Transcript: Jefferies Global Healthcare Conference 2025

May 29, 2025, 8:00 AM EDT - 1 year ago

Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference

May 15, 2025, 9:30 AM EDT - 1 year ago

Cabaletta Bio Quarterly report: Q1 2025

May 15, 2025, 7:00 AM EDT - 1 year ago

Cabaletta Bio Announces 2027 Rese-cel BLA Submission Anticipated in Myositis Following Recent FDA Alignment on Registrational Cohorts

May 13, 2025, 8:00 AM EDT - 1 year ago

Cabaletta Bio Proxy statement: Proxy Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Cabaletta Bio Proxy statement: Proxy Filing

Mar 31, 2025, 7:00 AM EDT - 1 year ago

Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 31, 2025, 7:00 AM EDT - 1 year ago

Cabaletta Bio Earnings release: Q4 2024

Mar 31, 2025, 7:00 AM EDT - 1 year ago

Cabaletta Bio Annual report: Q4 2024

Mar 19, 2025, 7:00 AM EDT - 1 year ago

Cellares and Cabaletta Bio Successfully Complete Manufacturing Technology Adoption Program for Rese-cel Using the Cell Shuttle™ Platform

Mar 3, 2025, 11:50 AM EST - 1 year ago

Cabaletta Bio Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 26, 2025, 8:00 AM EST - 1 year ago

Cabaletta Bio to Participate in the TD Cowen 45th Annual Health Care Conference

Feb 18, 2025, 10:21 AM EST - 1 year ago

UPDATE - Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings

Feb 18, 2025, 7:00 AM EST - 1 year ago

Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings

Feb 11, 2025, 8:00 AM EST - 1 year ago

Cabaletta Bio Announces Presentations Featuring Updated Clinical Data on Rese-cel at Upcoming Scientific Meetings in February

Feb 5, 2025, 10:30 AM EST - 1 year ago

Cabaletta Bio Transcript: Guggenheim SMID Cap Biotech Conference

Jan 29, 2025, 8:00 AM EST - 1 year ago

Cabaletta Bio to Participate in Guggenheim's SMID Cap Biotech Conference

Dec 4, 2024, 7:55 AM EST - 1 year ago

Cabaletta Bio Transcript: 7th Annual Evercore ISI HealthCONx Healthcare Conference

Nov 20, 2024, 6:30 AM EST - 1 year ago

Cabaletta Bio Transcript: Jefferies London Healthcare Conference 2024

Nov 18, 2024, 8:00 AM EST - 1 year ago

Cabaletta Bio Transcript: Status Update

Nov 18, 2024, 8:00 AM EST - 1 year ago

Cabaletta Bio Press release: Status Update

Nov 18, 2024, 8:00 AM EST - 1 year ago

Cabaletta Bio Slides: Status Update

Nov 14, 2024, 7:00 AM EST - 1 year ago

Cabaletta Bio Quarterly report: Q3 2024

Nov 14, 2024, 7:00 AM EST - 1 year ago

Cabaletta Bio Earnings release: Q3 2024

Nov 11, 2024, 10:00 AM EST - 1 year ago

Cabaletta Bio Transcript: Guggenheim Securities Inaugural Healthcare Innovation Conference

Sep 25, 2024, 4:30 PM EDT - 1 year ago

Cabaletta Bio to Present New and Updated Clinical Data on CABA-201 in Oral and Poster Presentations at ACR Convergence 2024

Sep 17, 2024, 11:30 AM EDT - 1 year ago

Cabaletta Bio Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 11, 2024, 9:00 AM EDT - 1 year ago

Cabaletta Bio Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 5, 2024, 8:00 AM EDT - 1 year ago

Cabaletta Bio Transcript: 2024 Wells Fargo Healthcare Conference

Sep 4, 2024, 4:50 PM EDT - 1 year ago

Cabaletta Bio Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 8, 2024, 7:15 AM EDT - 2 years ago

Cabaletta Bio Quarterly report: Q2 2024

Aug 8, 2024, 7:15 AM EDT - 2 years ago

Cabaletta Bio Earnings release: Q2 2024

Aug 8, 2024, 7:00 AM EDT - 2 years ago

Cabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 2, 2024, 8:00 AM EDT - 2 years ago

Cabaletta Bio to Participate in the Stifel 2024 Virtual Cell Therapy Forum

Jun 14, 2024, 8:00 AM EDT - 2 years ago

Cabaletta Bio Transcript: Study Update

Jun 14, 2024, 8:00 AM EDT - 2 years ago

Cabaletta Bio Press release: Study Update

Jun 14, 2024, 8:00 AM EDT - 2 years ago

Cabaletta Bio Slides: Study Update

Jun 14, 2024, 2:00 AM EDT - 2 years ago

Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201

May 15, 2024, 7:00 AM EDT - 2 years ago

Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update

May 15, 2024, 7:00 AM EDT - 2 years ago

Cabaletta Bio Quarterly report: Q1 2024

May 15, 2024, 7:00 AM EDT - 2 years ago

Cabaletta Bio Earnings release: Q1 2024

May 15, 2024, 7:00 AM EDT - 2 years ago

Cabaletta Bio Slides: Corporate Presentation

May 13, 2024, 8:00 AM EDT - 2 years ago

Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

Apr 23, 2024, 8:00 AM EDT - 2 years ago

Cabaletta Bio Proxy statement: Proxy Filing

Apr 23, 2024, 8:00 AM EDT - 2 years ago

Cabaletta Bio Proxy statement: Proxy Filing

Mar 21, 2024, 8:00 AM EDT - 2 years ago

Cabaletta Bio Earnings release: Q4 2023

Mar 21, 2024, 8:00 AM EDT - 2 years ago

Cabaletta Bio Annual report: Q4 2023

Mar 21, 2024, 7:00 AM EDT - 2 years ago

Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Feb 27, 2024, 8:00 AM EST - 2 years ago

Cabaletta Bio to Participate in Upcoming Investor Conferences in March

Feb 1, 2024, 4:30 PM EST - 2 years ago

Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis

Jan 31, 2024, 8:00 AM EST - 2 years ago

Cabaletta Bio to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Jan 9, 2024, 8:15 PM EST - 2 years ago

Cabaletta Bio Transcript: J.P. Morgan 42nd Annual Healthcare Conference 2024

Jan 9, 2024, 8:15 PM EST - 2 years ago

Cabaletta Bio Slides: FY 2024

Jan 2, 2024, 8:00 AM EST - 2 years ago

Cabaletta Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Nov 28, 2023, 4:30 PM EST - 2 years ago

Cabaletta Bio to Participate in the 6th Annual Evercore ISI HealthCONx Conference

Nov 28, 2023, 3:55 PM EST - 2 years ago

Cabaletta Bio's and Gracell's stock falls sharply as FDA investigates risks of CAR-T therapy

Nov 9, 2023, 7:00 AM EST - 2 years ago

Cabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 9, 2023, 7:00 AM EST - 2 years ago

Cabaletta Bio Quarterly report: Q3 2023

Nov 9, 2023, 7:00 AM EST - 2 years ago

Cabaletta Bio Earnings release: Q3 2023

Nov 6, 2023, 8:15 AM EST - 2 years ago

Cellares and Cabaletta Bio Partner to Evaluate Automated Manufacturing for CABA-201, Cabaletta's CD19-CAR T Cell Therapy on Cellares' Cell Shuttle Platform

Oct 30, 2023, 8:00 AM EDT - 2 years ago

Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in November

Sep 13, 2023, 2:15 PM EDT - 3 years ago

Cabaletta Bio Transcript: Morgan Stanley 21st Annual Global Healthcare Conference 2023

Sep 7, 2023, 1:50 PM EDT - 3 years ago

Cabaletta Bio Transcript: Citi 18th Annual BioPharma Conference

Aug 30, 2023, 8:00 AM EDT - 3 years ago

Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in September

Aug 10, 2023, 7:00 AM EDT - 3 years ago

Cabaletta Bio Reports Second Quarter 2023 Financial Results and Provides Business Update

Aug 10, 2023, 7:00 AM EDT - 3 years ago

Cabaletta Bio Quarterly report: Q2 2023

Aug 10, 2023, 7:00 AM EDT - 3 years ago

Cabaletta Bio Earnings release: Q2 2023

Achandler787 Jul. 4 at 2:28 PM

$CABA $LLY

0 · Reply

Achandler787 Jul. 4 at 2:25 PM

0 · Reply

Rolo2024 Jul. 4 at 2:14 AM

$CABA I only have 360 shares practically just broke even. I noticed in March 2024 we were at a high of $26 so why is our PT around $13.50 now? Anyone know?

2 · Reply

deweyeggbert Jul. 3 at 11:29 PM

$CABA both eyes on it.

0 · Reply

topstockalerts Jul. 3 at 10:57 AM

$CABA keep an eye on it

0 · Reply

raj4cena Jul. 3 at 3:39 AM

$CABA Any chance of this reaching 5?

2 · Reply

ABDULMOHSEN08 Jul. 3 at 12:50 AM

$CABA What is the price now?😅🤫

1 · Reply

Bronco6970 Jul. 2 at 10:17 PM

$CABA Abdul, where are you? Get ready to feel more pain.

1 · Reply

Achandler787 Jul. 2 at 8:22 PM

$CABA most shorts lose a lot of money. Maybe a couple a pros with real research are successful with mega trends —-not penny stock bio tech flippers. That’s Russian Roulette.

1 · Reply

pleasemoney Jul. 2 at 8:17 PM

$CABA how is your 2.50 eow prediction going @ABDULMOHSEN08? Any more insight to share with us?

0 · Reply

Achandler787 Jul. 2 at 8:17 PM

$CABA news/data is coming- that’s a certainty…if it’s good the set up is perfect! 🤩

0 · Reply

Moonman321 Jul. 2 at 7:11 PM

$CABA $FVRR $PLUG $SIDU you better get your ass in gear 🐻 🩸

0 · Reply

Swami747 Jul. 2 at 6:38 PM

$CABA Let’s go caballeros buy another 1000 shares for the semiquincentennial!!

0 · Reply

Bronco6970 Jul. 2 at 5:31 PM

$CABA we are going to $5 🚀🚀

1 · Reply

2tacos_plis Jul. 2 at 4:30 PM

$CABA Gap ups on a would be Friday mean 2 things to me. Sell for a small profit and buy back next week on the pullback gap fill. It ain’t easy being sleezy!

0 · Reply

WastedTrader Jul. 2 at 4:12 PM

$CABA increasing volume, increasing short interest and the price is struggling to stay down, short squeeze fuel ⛽️ just need the ignition (news) for the explosion 💥

0 · Reply

ABDULMOHSEN08 Jul. 2 at 4:11 PM

$CABA 😉😉🤣

0 · Reply

gata2016 Jul. 2 at 3:53 PM

$ICU We know pediatric treatment has already passed FDA. I would imagine there is a strong liklihood of adult population following suit. My low-end prediction for BO here is $125 at a modest $500M. At 1B, we are looking at a whopping $250/share. We arent far off my friends! $SLS $AUPH $FATE $CABA

2 · Reply

vu_jade Jul. 2 at 3:14 PM

$CABA $CCCC & $CRBU Back in the 3 pack of C’s for the revival!

2 · Reply

Moonman321 Jul. 2 at 2:45 PM

$CABA second half of the day will be good Squeezing those turds into the 250 anniversary

0 · Reply

ABDULMOHSEN08 Jul. 2 at 2:30 PM

$CABA Let's enjoy the view of the slide, first above and then below.

0 · Reply

venice868 Jul. 2 at 2:21 PM

$CABA sold thanks for the pump again

0 · Reply

Market Cap	520.15M
Revenue (ttm)	0.00
Net Income (ttm)	-167.86M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	8,593,000
Avg Vol	5,035,892
Day's Range	N/A - N/A
Shares Out	163.06M
Stochastic %K	80%
Beta	3.26
Analysts	Strong Sell
Price Target	$13.38